Abstract 1566P
Background
Participation rate in lung cancer screening (LCS) programs is challenging. The ILYAD (Initiative LYonnaise pour l’Amorçage du Dépistage) study main objective is to assess whereas various communication methods may improve participation rate among a population of eligible staffs of Lyon University Hospital (LUH).
Methods
In a previous work, we assessed the number of eligible employees at LUH. 838 peoples among 26,954 staffs were found eligible to LCS according to current French guidelines. We designed an LCS program dedicated to staffs from LHU. We provided specific email address, phone number, and an online tool. We applied three communication methods for participants recruitment. We started with common displays (flyers, posters) and general emailing. Then, we involved managers of the departments identified with high-risk employees and occupational medicine. Finally, we used specially trained nurses to meet the employees in their daily routine.
Results
From September 2022 to May 2024, 144 participants were included, resulting in a participating rate of 17.2%. 85 (59%) were included during the first period (common displays and emails), 17 (12%) during the second (targeting high-risk), and 44 (30%) during the third (face to face meeting). Institutional general emailing appeared as the best way of recruitment. Surprisingly, face-to-face interaction were not very efficient, principally due to people lack of commitment afterward. During this first round of screening, one positive screening lead to the diagnosis of a stage IA adenocarcinoma. Moreover, we diagnosed 14 early COPD (group A and B). Coronary calcifications were identified in 15 cases. 70% participants contacted us through the online tool.
Conclusions
Despite a population of healthcare employees and different communication strategies tested, our results showed a low LCS participation rate. These results enhanced the fact that population adherence to LCS program will be a critical issue to address properly in order to improve screening efficiency.
Clinical trial identification
Sponsor code: 69HCL22_0466; NCT05452200 N° IDRCB: 2022-A01203-40 Approved by ethic committee CPP OUEST III: 23/06/2022.
Editorial acknowledgement
Legal entity responsible for the study
Hospices Civils de Lyon.
Funding
AstraZeneca Volition Transdiag.
Disclosure
S. Couraud: Financial Interests, Personal and Institutional, Funding, consulting fees: AstraZeneca, Amgen, Boehringer Ingelheim, MSD, Novartis, Sanofi, Roche, Pfizer, BMS; Financial Interests, Institutional, Funding: Chugai, Lilly, Takeda, Janssen, Celgene, Transdiag, Volition, Adene, BD Bioscience; Financial Interests, Personal, Other, consulting fees: Health event, MaaT Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10